IMV News and Press, IMV Inc. From 12/03/20

37% (7/19) patients experienced clinical benefits lasting over 6 months 12-month overall survival rate of 66.1% Translational data confirms survivin-specific CD8+ T cell immune response in 87% of subjects which supports a direct link with DPX-Survivac’...

5 Biotech Stocks To Watch This Week When it comes to biotech stocks , there’s plenty to take into account. This goes for biotech penny stocks as well. Considering that many of these companies are in the preclinical or clinical stages, there’s a higher chance that t...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announced that the Company will host a key opinion leader (KOL) webcast on the treatment options in ovarian can...

IMV Inc. (IMV) Q3 2020 Earnings Conference Call November 12, 2020 08:00 ET Company Participants Pierre Labbé - CFO Frederic Ors - CEO Neil Berinstein - Hematologist & Affiliate Scientist, Sunnybrook Institute Joanne Schindler - CMO Conference Call Participants Jim Birchenough - Wells...

Gainers: EuroDry (EDRY) +64%.Innodata (INOD) +32%.Akers Biosciences (AKER) +30%.XPeng (XPEV) +29%.Cidara Therapeutics (CDTX) +27%.Fossil Group (FOSL) +26%.Li Auto (LI) +23%.Sino-Global Shipping America (SINO) +22%.Celsius Holdings (CELH) +21%.Five Prime Therapeutics (FPRX) +16%...

IMV (IMV): Q3 GAAP EPS of -C$0.13.Revenue of C$0.09M (-43.8% Y/Y)Shares -0.74% PM.Press Release For further details see: IMV reports Q3 results

Identification of PD-L1 as a potential Biomarker with 86% of clinical responses in patients with r/r DLBCL in our combination trial with Merck’s Keytruda® Cash and cash equivalents of $54.7M as of September 30 th , 2020 Expanded Board of Directors and...

Former Celgene Executive and Immunotherapy Industry Leader to Drive Development Opportunities and Path-to-Market Initiatives for IMV's Immunotherapy Pipeline IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immun...

IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announced that IMV’s executive management team ...